IgE-binding epitopes on allergen proteins

IgE-binding epitopes are specific structural regions on the surface of allergen proteins that are recognized and bound by allergen-specific Immunoglobulin E (IgE) antibodies. These epitopes are categorized as either linear, consisting of a continuous sequence of amino acids, or conformational, where residues are brought together by the protein's three-dimensional folding (Curin M, et al., 2017, "IgE epitopes of allergens"). The primary biological consequence of IgE binding to these epitopes is the cross-linking of IgE-FcεRI complexes on the surface of mast cells and basophils, which triggers the rapid release of inflammatory mediators like histamine (Pomés A, et al., 2018, "Epitopes of allergens: what can we learn for immunotherapy?"). This process is the fundamental driver of Type I hypersensitivity reactions, including allergic rhinitis, asthma, and life-threatening anaphylaxis. In the context of drug development, these epitopes are targeted through allergen-specific immunotherapy (AIT) and the design of recombinant hypoallergens, which aim to desensitize the immune system by inducing T-cell tolerance while minimizing IgE-mediated side effects (Valenta R, et al., 2010, "The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy"). Additionally, monoclonal antibodies are being engineered to specifically mask these epitopes or neutralize circulating IgE, offering a targeted approach to managing severe food and environmental allergies.

Other names

Allergenic epitopesIgE epitopesB-cell epitopes on allergensAntigenic determinantsAllergen-binding sites

Therapeutic strategies involve neutralizing IgE antibodies to prevent binding, masking epitopes with monoclonal antibodies to block IgE access, or modifying the epitopes (hypoallergens) to induce immune tolerance without triggering mast cell degranulation.